ClinicalTrials.gg
RecruitingNCT06757296Updated Feb 14, 2025

Endoscopic Conversion of Sleeve Gastrectomy to Single Anastomosis Sleeve-ileal Bypass (SASI) for Gastroesophageal Reflux (GERD), Primary and Secondary Non-responder.

An interventional study of Endoscopic SASI in Metabolic Syndrome, Severe Obesity and Reflux, Gastroesophageal, sponsored by Singapore Health Services. Recruiting at 3 sites in Singapore. Open to participants aged 21 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-02-14.

Sponsored by Singapore Health Services · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
500
Allocation
Not applicable
Ages
21 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Metabolic Syndrome with a site in Singapore — 7 open to participants now, 9 under way, none of them phase 3. Metabolic Syndrome · Singapore.

Started
2025
the only one that year
No phase
7 of 15
3 open now
Registered
11th of 15
by date
Lead sponsor
1 of 15
Singapore Health Services

Among the 15 studies in Metabolic Syndrome with a site in Singapore, this one is the only one that started in 2025, is one of 7 with no phase, and was the 11th registered.

Metabolic Syndrome

2,119 studies on the registry are indexed under Metabolic Syndrome; 350 are open to participants now.

Browse Metabolic Syndrome studies →

Open to participants now

7 of the 15 studies in Metabolic Syndrome with a site in Singapore are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Singapore have not opened yet or have stopped. Only those recruiting at a site in Singapore →

Who these studies take

Of the 234 Metabolic Syndrome studies recruiting now, 70 (30%) set no upper age limit and 135 (58%) stop at 75 or younger; 20 take children under 18; 81 take healthy volunteers.

This study: 21 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Metabolic Syndrome with a site in Singapore, or all of them as a file.
02

Study summary

The aim of this study is to determine the feasibility and effectiveness of endoscopic anastomosis of sleeve gastrectomy to ileum with a lumen apposing metal stent (LAMS) after a failed sleeve gastrectomy.

Read the detailed description

The current standard of care for patients who experience insufficient weight loss, weight re-gain or Type II diabetes relapse after a sleeve gastrectomy is a revisional laparoscopic sleeve gastrectomy.

However, such revisional procedure is commonly associated with high mortality and morbidity due to protein malnutrition. A noval bariatric procedure, single anastomosis sleeve ileal (SASI) bypass has emerged recently.

In this study, we are utilizing an incisionless novel endoscopic technique to efficiently replicate the anatomical features and physiological effects of SASI.

03

Conditions studied

  • Metabolic Syndrome
  • Severe Obesity
  • Reflux, Gastroesophageal
  • Bariatric Surgery

Keywords

  • SASI
  • Severe Obesity
  • Bariatric Surgery
04

Who can participate

Ages eligible
21 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subject must meet all the inclusion criteria to participate in this study and list each criterion.

  1. Age: 21-65 years
  2. Patients going for LSG at participating hospitals.
  3. Able to provide

Individuals below age 21 would not be recruited as this is a study in the adult population. Individuals above age 65 are excluded to minimize the procedure risk.

Exclusion criteria

Exclusion Criteria:

  1. Patients who were breast feeding or pregnant
  2. Severe psychiatric illness
  3. Eating disorder
  4. Active neoplastic disease
  5. End-stage renal disease
  6. Patients with bleeding diathesis
  7. Patients with pacemakers or implantable cardiac defibrillators
  8. Significant cardiovascular disease (e.g., acute myocardial infarction, congestive cardiac failure, ischemic heart disease, atrial fibrillation, sick sinus syndrome, supraventricular tachycardia)
  9. Any factors likely to limit adherence to study protocol (e.g., dementia; alcohol or substance abuse; history of unreliability in medication taking or appointment keeping; significant concerns about participation in the study from spouse, significant other or family members)
  10. Treatment with anti- agents that could not be temporarily discontinued
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
500 participants (estimated)

Study arms

  • Experimental
    Intervention

    Endoscopic SASI

    Procedure: Endoscopic SASI

Interventions

  • ProcedureEndoscopic SASI

    Endoscopic conversion to sleeve gastrectomy to SASI

06

What researchers measure

Primary outcomes

  1. Total amount of weight loss

    Amount of weight loss after endoscopic conversion to SASI will be measured in kg and will be reported in percentage (%).

    Time frame: 6 months

Secondary outcomes

  1. HbA1c

    HbA1c levels will be measured and reported in percentage (%)

    Time frame: 6 months

  2. GERD symptoms

    Quality of Life in Reflux And Dyspepsia (QoLRAD) is a questionnaire used to assess how gastroesophageal reflux disease (GERD) and dyspepsia (indigestion) affects a person's quality of life. The total score will be calculated from the questionnaire and a reduction in QoLRAD score over time will demonstrate improvement.

    Time frame: 6 months

Other outcomes

  1. Feasibility & Safety

    Technical success rate \& procedure related complications. Number of adverse events will be recorded at all times to determine the feasibility and safety of the study procedure.

    Time frame: 30 days

07

Study locations

3 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Aug 2026, 18 months after the start.

Of 627 non-industry interventional studies with no phase under Metabolic Syndrome, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 41. This study's planned 18 months is close to that.

Counting every sponsor, half of 677 studies reached it within 20 months; a quarter within 9 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 19, 2024
First posted
Jan 3, 2025
StartActual
Feb 3, 2025
Primary completionEst.
Aug 30, 2026
CompletionEst.
Dec 31, 2026
Last update
Feb 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06757296
Lead sponsor
Singapore Health Services
Collaborators
Changi General Hospital, Sengkang General Hospital
Responsible party
Chin Hong Lim (Doctor, Singapore Health Services) — Principal investigator
First posted
Jan 3, 2025
Start date
Feb 3, 2025
Primary completion
Aug 30, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Feb 14, 2025

Study contacts

Chin Hong Lim, MD
Contact
lim.chin.hong@singhealth.com.sg
62223322
Wei Min Chong, MSc
Contact
chong.wei.min@sgh.com.sg
Chin Hong Lim, MD
principal investigator · Singapore General Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion